JPM vs TRIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
TRIN exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a critical dividend payout ratio of 112.76%, indicating the dividend is currently unsustainable. While the P/E ratio appears attractive at 8.28, this is offset by a high PEG ratio of 5.14 and a sharp 30.5% year-over-year decline in earnings. Despite positive analyst sentiment and a high Graham Number, the combination of poor liquidity (Current Ratio 0.45) and negative earnings growth suggests a value trap scenario.
Compare Another Pair
Related Comparisons
JPM vs TRIN: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Trinity Capital Inc. (TRIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.